Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27

Patent metadata

Field	Value
Publication number	US-10940150-B2
Application number	US-201515329722-A
Country	US
Kind code	B2
Filing date	Jul 28, 2015
Priority date	Jul 28, 2014
Publication date	Mar 9, 2021
Grant date	Mar 9, 2021

Abstract

The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27.

First claim

The invention claimed is:

1. A method for treating cancer comprising administering a pharmaceutically effective amount of a thymine derivative to a patient having cancer who is undergoing chemotherapy, radiotherapy and/or cancer immunotherapy,
wherein the thymine derivative is a thymine derivative of general formula (VI) and/or of general formula (VI′)

wherein:
the substituent A is —H, halogen, —CH 3 , an alkynyl residue, phenyl or a thiophene residue,
the linker L is an optionally substituted C1 to C6 alkyl residue, an optionally substituted phenyl, benzyl or pyridine residue,

for thymine derivative of general formula (VI) and L is an optionally substituted C1 to C6 alkyl residue, an optionally substituted phenyl, benzyl or pyridine residue, or

for thymine derivative of general formula (VI′)
wherein
the substituents B 1 and B 2 independently of one another are —H, —CH 3 , —CF 3 , —F or —Cl,
A 1 is —CH 2 —, —CHOR, —CHF— or —CHOC(═O)R,
A 3 is —CH 2 —, —CHOR, —CHF—, —CHOC(═O)R or —CHK—, wherein K is an optionally substituted five-membered ring nitrogen heterocycle,
G is —CH 2 —, —CH 2 O— or —O—,
Y is S, NR, carboxyl, carbonyl or amide,

wherein R is H or a C 1 to C 8 alkyl residue,
the substituent R y is H, OH, —CR a R b R c , an optionally substituted cyclic or polycyclic aryl residue or an optionally substituted oxygen or nitrogen heterocycle,
wherein R a , R b and R c independently of one another are selected from H and cyclic residues,

the substituent R N is a benzoyl residue
wherein at least one of the residues R a , R b and R c is H and at least one of the residues is a cyclic residue, selected from optionally substituted cyclic or polycyclic aryl residues and optionally substituted heterocycles.

2. The method for treating cancer according to claim 1 , wherein R y is selected from H, general formula (III) or formula (IV)

wherein is a covalent linkage to general formula (VI) or (VI′),
X is N or CH,
Z is a single bond, CH 2 , O, C(═O), S or NR x ,
R x is an optionally substituted and/or branched C 1 to C 4 alkyl residue,
R 1 , R 2 , R 3 and R 4 each independently of one another are —H, -halogen, —NO 2 , —CN, —NR 2 and —SR, —OR, —COOR, —COR, —R, a C 2 to C 4 vinyl residue or an aryl residue, wherein R is H or C 1 to C 8 alkyl residue.

3. The method for treating cancer according to claim 2 , wherein R y is selected from H and OH and A 3 is —CHK—, where K is an optionally substituted five-membered ring nitrogen heterocycle.

4. The method for treating cancer according to claim 2 , wherein Z is O, C(═O) or S and X is N or CH.

5. The method for treating cancer according to claim 1 , wherein Y is NR or an amide group, where R is H or C 1 to C 8 alkyl residue.

6. The method for treating cancer according to claim 2 , wherein R 1 , R 3 and optionally R 4 are H.

7. The method for treating cancer according to claim 2 , wherein R y according to formula (IV), R 1 is H, R 2 and R 3 independently of one another are H or an optionally OH-functionalized C 1 to C 5 alkyl residue or an optionally substituted C 2 to C 4 vinyl residue.

8. The method for treating cancer according to claim 2 , wherein R y according to formula (III), R 1 , R 3 and R 4 are H and R 2 is H, -halogen, —COR or an optionally substituted phenyl residue, wherein this R in formula (III) is H or an optionally OH-functionalized C 1 to C 5 alkyl residue.

9. The method for treating cancer according to claim 1 , wherein the thymine derivative is already administered before the start of the chemotherapy, radiotherapy and/or cancer immunotherapy and the administration of the thymine derivative is continued during these therapies.

10. The method for treating cancer according to claim 9 , wherein the administration of the thymine derivative is started 15 min to 4 hours before the start of the chemotherapy, radiotherapy and/or cancer immunotherapy.

11. The method for treating cancer according to claim 1 comprising administering a pharmaceutically effective amount of a pharmaceutical formulation containing the thymine derivative to a patient having cancer who is undergoing chemotherapy, radiotherapy and/or cancer immunotherapy.

12. The method for treating cancer according to claim 1 , wherein the thymine derivative is a thymine derivative of general formula (VI′)

wherein:
the substituent A is —H, halogen, —CH 3 , —C═O, an alkynyl residue, phenyl or a thiophene residue,
the linker L is an optionally substituted C 1 to C 6 alkyl residue, an optionally substituted phenyl, benzyl or pyridine residue,

or
wherein
the substituents B 1 and B 2 independently of one another are —H, —CH 3 , —CF 3 , —F or —Cl,
A= 1 is —CH 2 —, —CHOR, —CHF— or —CHOC(═O)R,
A 3 is —CH 2 —, —CHOR, —CHF—, —CHOC(═O)R or —CHK—, wherein K is an optionally substituted five-membered ring nitrogen heterocycle,
G is —CH 2 —, —CH 2 O— or —O—,
Y is S, NR, carboxyl, carbonyl or amide,

wherein R is H or a C 1 to C 8 alkyl residue,
the substituent R y is H, OH, —CR a R b R c , an optionally substituted cyclic or polycyclic aryl residue or an optionally substituted oxygen or nitrogen heterocycle,
wherein R a , R b and R c independently of one another are selected from H and cyclic residues,

wherein at least one of the residues R a , R b and R c is H and at least one of the residues is a cyclic residue, selected from optionally substituted cyclic or polycyclic aryl residues and optionally substituted heterocycles.

Assignees

• Univ Dresden Tech

Inventors

• Schroeder Michael
• Zhang Yixin
• Heinrich Joerg-Christian
• Haupt Joachim
• Donakonda Sainitin
• Lennig Petra

Classifications

• A61K31/708

  having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07D239/553

  with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• C07F9/65616

  containing the ring system [IMAGE cpc-sch-C07F-1006.gif] having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs · CPC title